Recce Pharmaceuticals Valuation Multiples

Recce Pharmaceuticals Overview

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.

Founded

2007

HQ

Employees

N/A

Website

recce.com.au

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4M

EBITDA: ($13M)

EV

$125M

Valuation Multiples

Multiples.vc

Start free trial

Recce Pharmaceuticals Financials

Recce Pharmaceuticals reported last 12-month revenue of $4M and negative EBITDA of ($13M).

In the same LTM period, Recce Pharmaceuticals generated $4M in gross profit, ($13M) in EBITDA losses, and had net loss of ($14M).

Recce Pharmaceuticals P&L

In the most recent fiscal year, Recce Pharmaceuticals reported revenue of — and net income of —.

Recce Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Recce Pharmaceuticals Stock Performance

Recce Pharmaceuticals has current market cap of $118M, and enterprise value of $125M.

Recce Pharmaceuticals' stock price is $0.41.

Recce Pharmaceuticals Valuation Multiples

Recce Pharmaceuticals trades at 33.9x EV/Revenue multiple, and (9.7x) EV/EBITDA.

Recce Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Recce Pharmaceuticals has market cap of $118M and EV of $125M.

Equity research analysts estimate Recce Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Recce Pharmaceuticals has a P/E ratio of (8.7x).

Recce Pharmaceuticals Margins & Growth Rates

Recce Pharmaceuticals' revenue in the last 12 month declined by (1%).

Recce Pharmaceuticals' rule of 40 is (472%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Recce Pharmaceuticals' rule of X is (495%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Recce Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Recce Pharmaceuticals M&A Activity

Recce Pharmaceuticals acquired XXX companies to date.

Last acquisition by Recce Pharmaceuticals was on XXXXXXXX, XXXXX. Recce Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Recce Pharmaceuticals Investment Activity

Recce Pharmaceuticals invested in XXX companies to date.

Recce Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Recce Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).